New and Emerging Non-Postsynaptic Dopamine Modulating Antipsychotic Treatments for the Management of Patients with Schizophrenia in the Department of Veterans Affairs
Released On
April 13, 2023
Expires On
April 13, 2024
Media Type
Internet
Completion Time
60 minutes
Specialty
Primary Care
Topic(s)
Schizophrenia
This activity is jointly provided by Med Learning Group and Ultimate Medical Academy/Complete Conference Management (CCM.
This activity is supported by an educational grant from Sunovion and Otsuka.
Credit Available
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
- Nurses — 1.0 Contact Hours
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This activity is intended for psychiatrists, psychiatric nurses, and nurse practitioners and within the VA system involved in the management of patients with schizophrenia.
Program Overview
This virtual live program has been designed to meet the educational needs of healthcare providers in the Department of Veterans Affairs, including psychiatrists involved in the management of patients with schizophrenia. We aim to help HCPs within the VA system assess the clinical benefits and disadvantages associated with dopamine-modulating antipsychotic medications approved for the management of schizophrenia and also interpret data from clinical trials assessing the clinical profiles of new and emerging therapies for the management of schizophrenia that have unique targets and mechanisms of action.
Learning Objectives
Upon completion of this activity, attendees should be able to:
- Assess the clinical benefits and disadvantages associated with dopamine-modulating antipsychotic medications approved for the management of schizophrenia
- Interpret data from clinical trials assessing the clinical profiles of new and emerging therapies for the management of schizophrenia that have unique targets and mechanisms of action
Program Chair
Christoph U. Correll, MD
Professor of Psychiatry
Zucker School of Medicine at Hofstra/Northwell
Hempstead, NY
Professor of Child and Adolescent Psychiatry
Charité University Medicine
Berlin, Germany
Physician Accreditation Statement
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
Physician Credit Designation
Med Learning Group designates this virtual live activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the virtual live activity
Nursing Credit Information
Purpose: This program would be beneficial for nurses involved in the care of patients with schizophrenia.
CNE Credits: 1.0 ANCC Contact Hour.
CNE Accreditation Statement
Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
Disclosure Policy Statement
In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
Disclosures of Conflicts of Interest
- Dr. Christoph U. Correll
- Royalties: UpToDate
- Consulting Fees : AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Boehringer-Ingelheim, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Merck, Mindpax, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Newron, Noven, Otsuka, Pharmabrain, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Seqirus, SK Life Science, Sunovion, Sun Pharma, Supernus, Takeda, Teva, Viatris
- Ownership Interest : Cardio Diagnostics, Mindpax, LB Pharma, Quantic
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with ineligible companies related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Sylvia Hanna, MD Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Joan Duer-Hefele, RN, MA CCRC, has nothing to disclose.
Marissa Mays-Verman, Program Manager for Med Learning Group, has nothing to disclose.
Alexis Klinger, Program Coordinator for Med Learning Group, has nothing to disclose.
Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
Method of Participation
There are no fees for participating and receiving CME credit for this virtual live activity. To receive CME/CNE credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form.
Certificates will be emailed to the participant.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
Disclaimer
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at info@medlearninggroup.com
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://www.medlearninggroup.com/privacy-policy/"
Americans with Disabilities Act
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
Copyright © 2023 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.